Moxifloxacin--a new fluoroquinolone antibacterial.
Moxifloxacin (Avelox - Bayer plc), the latest fluoroquinolone antibacterial to be launched in the UK, is licensed for the oral treatment of adults with community-acquired pneumonia, acute exacerbation of chronic bronchitis or acute sinusitis. The company claims that the drug provides "rapid relief from chest infections". Here we review the place of moxifloxacin in treating patients with respiratory tract infections.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016527:Drug Costs; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D011014:Pneumonia / Q000188:drug therapy*; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012140:Respiratory Tract Diseases / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin